Kindred Biosciences Submits Final Major New Animal Drug Application Technical Section for Safety for Mirataz to FDA and Launches KindredBio Equine Website

San Francisco, CA (September 30, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Safety technical section of the New Animal Drug Application (NADA) for Mirataz™ (mirtazapine 2% transdermal ointment, KIND-010).  This is the final major technical section to be submitted for Mirataz. The Chemistry, Manufacturing, and Controls technical section was submitted in May 2016 and the Effectiveness technical section was submitted in August 2016.

In the target animal safety study, Mirataz was generally well-tolerated and no significant safety concerns were identified at 1X, 3X, or 5X the proposed label dose (2 mg/cat applied once daily to the inner pinna of the ear) for 42 consecutive days of transdermal application. At the proposed label dose, topical administration of mirtazapine ointment was associated with mild, reversible skin changes at the site of dose application (ear).

Richard Chin, CEO of KindredBio, stated, “We are pleased to bring Mirataz one step closer to approval. Weight loss in cats is a serious and potentially fatal problem, and there is currently no drug approved for the treatment of this unmet medical need. We believe that, with its excellent efficacy and safety profile, Mirataz will be an important new drug for feline patients. Like our other programs, the Mirataz program was completed ahead of time and on budget. I want to congratulate the KindredBio team and our investigators for their dedication and hard work.”

KindredBio also announced the launch of the KindredBio Equine website (www.kindredbioequine.com).  This website may also be accessed via KindredBio’s homepage (www.kindredbio.com).

About Kindred Biosciences

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.  The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses.  The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our expectations about the trials, regulatory approval, manufacturing, distribution and commercialization of our current and future product candidates, and statements regarding our anticipated revenues, expenses, margins, profits and use of cash.

These forward-looking statements are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements.  These risks include, but are not limited to, the following:  our limited operating history and expectations of losses for the foreseeable future; the absence of revenue from our product candidates for the foreseeable future; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our lead product candidates, which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our product candidates; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to develop a satisfactory sales organization; our significant costs of operating as a public company; our potential inability to obtain patent protection and other intellectual property protection for our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.

For a further description of these risks and other risks that we face, please see the risk factors described in our filings with the U.S. Securities and Exchange Commission (the SEC), including the risk factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K and any subsequent updates that may be contained in our Quarterly Reports on Form 10-Q filed with the SEC.  As a result of the risks described above and in our filings with the SEC, actual results may differ materially from those indicated by the forward-looking statements made in this press release.   Forward-looking statements contained in this press release speak only as of the date of this press release and we undertake no obligation to update or revise these statements, except as may be required by law.

Contact
Russell Radefeld
KindredBio
russell.radefeld@kindredbio.com
(650) 701-7904

KindredBio supports New Horizon Ranch – both working to strengthen the bond between horses and humans

KindredBio is a veterinary biopharmaceutical company based in Burlingame, CA that is focused on a strong development pipeline serving the horse with the motto “best medicines for our best friends.” KindredBio’s co-founder and many employees are horse people and advocates for the bond between horses and people with an understanding of how these animals change people’s lives. The value of the horse goes way beyond high end athletes such as our Olympic horses or Kentucky Derby winners.  Even retired or back yard horses touch human lives in unimaginable ways.

New Horizon ranch is a therapeutic riding center located in Rantoul, KS.  When you think “therapeutic riding,” most people imagine physically disabled children riding a horse.  That is partly true, but there is so much more to the purpose of the horses at New Horizon Ranch.  New Horizon Ranch serves children, teens, adults and seniors in need through various programs such as Giddy up and Read, Silver Spurs, Hippotherapy, Mending Fences, and summer day camps.  New Horizon also partners with local facilities and programs to support the underprivileged and elderly communities through equine assisted activities.

Dr. Valentine Williams, the Director of Veterinary Affairs at KindredBio, explains how she, KindredBio, and New Horizon all share their feverish desire to serve the horse and the people alongside them. “I sit on the board at New Horizon Ranch and, as they celebrate 10 years in the making, I have watched them profoundly influence the lives of so many people through the horse. Not only the riders and receivers of the service, but the families and the horses themselves.  The riding center’s horses, many of which are no longer able to serve in their traditional use, become these kid’s best friends and often the high point of their week.  Parents who would never be able to afford equine assisted activities are able to watch their kids grow and be transformed by the relationship with these horses through the amazing people that volunteer and support this community.  There are endless numbers of volunteer hours and financial supporters that make this happen for this community.  It all starts here.  The ways in which we can get involved in our communities changing lives is how we impact the world in our own way.  KindredBio’s founders and employees support communities changing lives through horses such as New Horizon Ranch.  It is the people within the company that allow this to happen at this level. We can all partner to promote wellness and health in horses that transcends animals to wellness and health (mental and physical) in people.”

Please visit the websites for both KindredBio and New Horizon Ranch to see how they are developing, serving, and building on the bond between horse and human.

http://KindredBio.com/

http://newhorizonranch.org/

Kindred Biosciences to Present at 2016 Ladenburg Thalmann Healthcare Conference

San Francisco, CA (September 20, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced Dr. Richard Chin, President and CEO, will be presenting at the Ladenburg Thalmann Healthcare Conference in New York City on Tuesday, September 27, 2016 at 11:00 AM EDT. The conference is being held at the Sofitel Hotel.

An archived version of the webcast and presentation will be available for 30 days on the Company’s website: http://kindredbio.com/investor-relations/events.

About Kindred Biosciences, Inc.

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.  The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses.  The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

Contact
Russell Radefeld
KindredBio
russell.radefeld@kindredbio.com
(650) 701-7904

Kindred Biosciences to Participate in a BIO Animal Biotech Summit Panel

San Francisco, CA (September 14, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Stephen Sundlof, DVM, PhD, Chief Scientific Officer and Executive Vice President, Regulatory Affairs and Quality, will be serving on a panel at the BIO Animal Biotech Summit in Bethesda, Maryland on Thursday, September 22, 2016 at 3.30pm EDT. The panel discussion, titled “Barriers to Innovation: Regulation and Politics,” will discuss the role of regulation in facilitating or impeding technological innovation. The conference is being held in the Grand Ballroom of the Bethesda Marriott.

About Kindred Biosciences, Inc.

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.  The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses.  The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

Contact
Russell Radefeld
KindredBio
russell.radefeld@kindredbio.com
(650) 701-7904

Kindred Biosciences Submits New Animal Drug Application Technical Section for Effectiveness for Mirataz to FDA

San Francisco, CA (August 22, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission of the Effectiveness Technical Section of the New Animal Drug Application for Mirataz™ (mirtazapine transdermal ointment) to the Food and Drug Administration (FDA) for the management of weight loss in cats. The Chemistry, Manufacturing, and Controls Technical Section was submitted in May 2016 and the Company plans to submit the Safety Technical Section in the third quarter of 2016.

The multicenter, randomized, double-blind, placebo-controlled pivotal field study enrolled 231 cats to assess the effectiveness of Mirataz in stimulating weight gain in cats. The primary endpoint was percentage change in body weight from Day 1 to Week 2. At Week 2, the mean percent increase in body weight from Day 1 was 4.07% in the KIND-010 group (n=90), versus 0.29% in the placebo group (n=97) (p<0.0001). Based on a review of the safety data, the drug appears to be well tolerated.

“We are excited about the market potential for Mirataz and are pleased to bring this program one step closer to approval. Managing weight loss in cats is a serious unmet medical need, with an estimated 9 million cats in the U.S. suffering from inappetence. As a transdermal product, Mirataz is an attractive alternative for veterinarians and owners to administering a drug orally to cats. I want to thank the KindredBio team and our investigators for their hard work as we advance our plan to launch Mirataz,” stated Richard Chin, M.D., President and CEO of KindredBio.

Weight loss is one of the leading causes of veterinary visits among cat owners, and a veterinarian will see on average 7 cats per week with this condition. In many cases, significant weight loss can lead to liver failure and ultimately death. Currently, there are limited options for the management of weight loss in cats, none of which include an FDA-approved transdermal option. As a transdermal product, it is formulated using KindredBio’s Accusorb™ technology, which results in high and predictable absorption. About 80% of veterinarians surveyed have indicated their intent to use the product, based on the Company’s market research.

About Kindred Biosciences

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.  The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses.  The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our expectations about the trials, regulatory approval, manufacturing, distribution and commercialization of our current and future product candidates, and statements regarding our anticipated revenues, expenses, margins, profits and use of cash.

These forward-looking statements are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements.  These risks include, but are not limited to, the following:  our limited operating history and expectations of losses for the foreseeable future; the absence of revenue from our product candidates for the foreseeable future; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our lead product candidates, which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our product candidates; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to develop a satisfactory sales organization; our significant costs of operating as a public company; our potential inability to obtain patent protection and other intellectual property protection for our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.

For a further description of these risks and other risks that we face, please see the risk factors described in our filings with the U.S. Securities and Exchange Commission (the SEC), including the risk factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K and any subsequent updates that may be contained in our Quarterly Reports on Form 10-Q filed with the SEC.  As a result of the risks described above and in our filings with the SEC, actual results may differ materially from those indicated by the forward-looking statements made in this press release.   Forward-looking statements contained in this press release speak only as of the date of this press release and we undertake no obligation to update or revise these statements, except as may be required by law.

Contact
Russell Radefeld
KindredBio
russell.radefeld@kindredbio.com
(650) 701-7904

Kindred Biosciences Announces Second Quarter 2016 Financial Results

San Francisco, CA (August 8, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2016 and provided updates on its programs.

“We are on track to launch our two lead product candidates by the first half of next year, and transition to revenue generation less than five years after KindredBio was founded. During the quarter we advanced Mirataz™, mirtazapine transdermal gel (formerly known as KIND-010), for the management of weight loss in cats, reporting positive results from a pivotal study. In addition, preparations are progressing as planned for the commercial launch of Zimeta™, dipyrone injection, for fever in horses. Our deep pipeline is supported by our strong cash position, and features an industry-leading biologics program with substantial revenue potential. Our most promising biologics candidates include treatments for anemia in cats and atopic dermatitis in dogs, both of which are currently undergoing pilot filed studies,” stated Richard Chin, M.D., President and CEO of KindredBio. “I am pleased with our rapid progress as we deliver on our strategy of quickly and cost-efficiently developing animal health therapeutics.”

Development and Corporate Updates

With more than 20 programs in development, KindredBio continues to advance a diversified portfolio of validated molecules in a capital efficient manner.  Recent highlights include:

  • The Company is preparing for the commercial launch of Zimeta, for the treatment of pyrexia (fever) in horses. All major technical sections of the New Animal Drug Application (NADA) have been submitted to the Food and Drug Administration (FDA). The Company anticipates approval of Zimeta in the first half of 2017. Zimeta is expected to be the first FDA-approved product for fever in horses, a significant and widely prevalent unmet medical need.
  • In May 2016, KindredBio announced positive topline results from the pivotal field study of Mirataz, for the management of weight loss in cats. Inappetence is a serious unmet medical need in cats, and can lead to hepatic failure. It is one of the leading causes for veterinary visits among cat owners.    The Company expects to file the Effectiveness and Safety technical sections of the NADA with the FDA in the third quarter of 2016, having filed the Chemical, Manufacturing, and Controls technical section earlier this year.
  • The Company has initiated a pilot field study of epoCat™, feline erythropoietin, for the control of non-regenerative anemia in cats. This study is underway with several clinical sites.
  • KindredBio conducted a pilot laboratory study to demonstrate the effectiveness and safety of two formulations of KIND-014, a development candidate for the treatment of equine gastric ulcers. Both formulations were well-tolerated and showed positive results for efficacy, as measured by gastric pH.
    The Company initiated a pilot field study earlier this year, which has completed enrollment and is expected to be completed in the third quarter of 2016.
  • The Company is finalizing the formulation for KIND-015, a development candidate for metabolic syndrome in horses, following which it expects to initiate a pilot field efficacy study by the end of 2016.
  • In June 2016, KindredBio announced the initiation of a pilot field study of atopic dermatitis in dogs, the purpose of which is to assess safety and efficacy of several molecules, including anti-cytokine antibodies. Based on the results, the Company will select certain product candidate(s) for further development.
  • The Company has completed the first stage of a pilot field study in sick or septic foals to assess safety and efficacy of anti-TNF. All five foals enrolled survived to day 7, the primary endpoint of the study. The second stage of the study is planned for early 2017, during the next foaling season.
  • The Company’s antibodies against cytokines and immune checkpoints continue to progress on track, with initial pilot studies for some expected in 2016. KIND-Bodies, a novel biologics scaffold with certain advantages over antibodies, including bispecific binding, is also proceeding on track.
  • The Company has completed construction and is undergoing commissioning of a state-of-the-art GMP biologics manufacturing plant. This facility is believed to be one of the first in the world dedicated to veterinary biologics.

Second Quarter and Six Month 2016 Financial Results

For the quarter ended June 30, 2016, KindredBio reported a net loss of $4.9 million or $0.25 per share, as compared to a net loss of $6.9 million or $0.35 per share for the same period in 2015. For the six months ended June 30, 2016, net loss was $11.0 million or $0.55 per share, as compared to a net loss of $13.6 million or $0.69 per share for the same period in 2015.

Total research and development expenses for the three and six months ended June 30, 2016 were $3.2 million and $6.6 million, respectively, compared to $5.0 million and $9.8 million for the same periods in 2015.  Stock-based compensation expense was $0.4 million and $0.7 million for the three and six months ended June 30, 2016 as compared to $0.5 million and $0.9 million for the same periods in 2015.  The decrease in research and development expenses in 2016 compared to 2015 was primarily due to lower field trial and material costs including consulting expenses, lower payroll and related expenses as a result of the Company’s restructuring in January and lower stock based compensation expense.  The prior year’s expenses also included costs related to pivotal studies for programs that have been completed or discontinued.

Total general and administrative expenses of $1.9 million and $3.9 million for the three and six months ended June 30, 2016 remained unchanged compared to the same periods in 2015. Higher payroll, corporate and marketing expenses were offset by lower consulting, legal and professional fees, as well as lower stock-based compensation expense. Stock-based compensation expense was $0.5 million and $1.0 million for the three and six months ended June 30, 2016 as compared to $0.6 million and $1.2 million for the same periods in 2015.

The Company recorded a restructuring charge of $655,000 for payroll related costs, which was paid in the first quarter of 2016, in order to streamline its development programs and extend its cash runway.

As of June 30, 2016, KindredBio had $66.3 million in cash, cash equivalents and investments, compared with $77.6 million as of December 31, 2015. The decrease was primarily due to cash used in operating activities of approximately $10.6 million.

For the 2016 calendar year the Company reiterates its previous guidance for operating expenses to be in the range of $24 million to $26 million, excluding the impact of stock-based compensation expense and the impact of acquisitions, if any. The Company’s anticipated expenditures for the remainder of the year include regulatory costs associated with the filing of registration of Mirataz, preparing for the commercial launch of Zimeta, as well as the continued development of its pipeline candidates.

Webcast and Conference Call

KindredBio will host a conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.   Interested parties may access the call by dialing toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally, and using conference ID 54160476.

About Kindred Biosciences

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.  The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses.  The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our expectations about the trials, regulatory approval, manufacturing, distribution and commercialization of our current and future product candidates, and statements regarding our anticipated revenues, expenses, margins, profits and use of cash.

These forward-looking statements are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements.  These risks include, but are not limited to, the following:  our limited operating history and expectations of losses for the foreseeable future; the absence of revenue from our product candidates for the foreseeable future; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our lead product candidates, which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our product candidates; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to develop a satisfactory sales organization; our significant costs of operating as a public company; our potential inability to obtain patent protection and other intellectual property protection for our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.

For a further description of these risks and other risks that we face, please see the risk factors described in our filings with the U.S. Securities and Exchange Commission (the SEC), including the risk factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K and any subsequent updates that may be contained in our Quarterly Reports on Form 10-Q filed with the SEC.  As a result of the risks described above and in our filings with the SEC, actual results may differ materially from those indicated by the forward-looking statements made in this press release.   Forward-looking statements contained in this press release speak only as of the date of this press release and we undertake no obligation to update or revise these statements, except as may be required by law.

Contact

Russell Radefeld
KindredBio
russell.radefeld@kindredbio.com 
(650) 701-7904

 

Kindred Biosciences to Announce Second Quarter 2016 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Monday, August 8, 2016

San Francisco, CA (July 26, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its second quarter 2016 financial results on August 8, 2016 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.

Interested parties may access the call by dialing toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally, and using conference ID 54160476.

 

About Kindred Biosciences

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.  The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses.  The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

Contact

Russell Radefeld
KindredBio
russell.radefeld@kindredbio.com
(650) 701-7904

Kindred Biosciences Announces Initiation of Pilot Field Study of Atopic Dermatitis and Other Updates

San Francisco, CA (June 14, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced the initiation of a pilot field study designed to test several molecules, including anti-cytokine antibodies, in dogs with atopic dermatitis.

The pilot field study in dogs with atopic dermatitis is a multi-center pilot study to assess safety and efficacy of several molecules, and to determine the candidate(s) that will be taken into further development.

In addition, KindredBio provided an update on its equine biologics program. The first stage of a pilot field study in sick or septic foals to assess safety and efficacy of anti-TNF has been completed.  Of the five foals enrolled, all survived to day 7, the primary endpoint of the study.

“We are very pleased to be making rapid progress in our biologics programs and we are excited about our burgeoning pipeline for atopic dermatitis. We are also encouraged by the 100% survival data in foals in a condition that can often result in 50% mortality,” said Richard Chin, M.D., President and Chief Executive Officer.

About Kindred Biosciences

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.  The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats, and horses.  The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

For more information or to download the corporate presentation, visit www.KindredBio.com. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our expectations about the trials, regulatory approval, manufacturing, distribution and commercialization of our current and future product candidates, and statements regarding our anticipated revenues, expenses, margins, profits and use of cash.

These forward-looking statements are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements.  These risks include, but are not limited to, the following:  our limited operating history and expectations of losses for the foreseeable future; the absence of revenue from our product candidates for the foreseeable future; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our lead product candidates, which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our product candidates; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to develop a satisfactory sales organization; our significant costs of operating as a public company; our potential inability to obtain patent protection and other intellectual property protection for our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.

For a further description of these risks and other risks that we face, please see the risk factors described in our filings with the U.S. Securities and Exchange Commission (the SEC), including the risk factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K and any subsequent updates that may be contained in our Quarterly Reports on Form 10-Q filed with the SEC.  As a result of the risks described above and in our filings with the SEC, actual results may differ materially from those indicated by the forward-looking statements made in this press release.   Forward-looking statements contained in this press release speak only as of the date of this press release and we undertake no obligation to update or revise these statements, except as may be required by law.

Contact
Russell Radefeld
KindredBio
russell.radefeld@kindredbio.com
(650) 701-7904

World’s Top Show Jumper, McLain Ward, wins the $15,000 KindredBio Jumper Prix

Saugerties, NY (June 12, 2016) The HITS-on-the-Hudson III at the Grand Prix Stadium saw some excellent competition on Saturday and we were excited to see the action around the $15,000 KindredBio 1.40M Jumper Prix.

McLain Ward, a two-time Olympic gold medalist and currently ranked the #1 show jumper in the world, aboard Best Buy, a nine-year-old Holsteiner mare owned by Double H Farm, topped the competition. The team was clean in the first round along with 8 other horse and rider combinations.  Ward and Best Buy had a fast and clean jump-off round, navigating the tough track in a fast 31.774 seconds.

“It’s great to have their support in our sport,” said Ward of KindredBio’s sponsorship in the equine industry. “A lot of care goes into these horses, and companies that provide a veterinary service to keep these animals competing and healthy are important.”

Denise Bevers, Co-Founder and Chief Operating Officer, said, “Congratulations to McLain Ward and Best Buy for winning the KindredBio Jumper Prix at HITS Saugerties!  I had the pleasure of watching McLain and Rothchild win the AIG $1 Million Grand Prix at HITS Thermal this year and find it very exciting to watch McLain develop horses like Best Buy in a class such as the 1.40M that KindredBio is sponsoring.”

Read more about McLain’s win and the event details at the HITS website.

 

Place Horse Owner Rider Prize Rd. 1 Faults JO Faults JO Time
1 Best Buy Double H Farm McLain Ward $4,350 0 0 31.774
2 Welfare Shalanno Farms LLC Fernando Lozinsky $3,150 0 0 32.579
3 Out Of Ireland The Edge Laura Chapot $2,100 0 0 33.134
4 Cecotto’s As Jennifer Rowland Kevin Mealiff $1,400 0 0 35.063
5 Caspar’s Lasino Market Street, Inc. Anne Kursinski $1,100 0 4 34.694
6 Doutzen Morgan Ward Morgan Ward $800 0 4 37.240
7 KM Whatever RV Beyaert Farm Inc. Mattias Tromp $650 0 8 33.314
8 Candori Rebecca Lewis Max Nieberg $550 0 8 47.701
9 Pretzel Logic Megan McDermott Kevin McCarthy $450 4
10 Shooting Star Mary Chapot Laura Chapot $450 4

 

The winner from Week II was Jeffery Welles and Calais and Week I was Laura Chapot and Out of Ireland.  Chapot won the $10,000 Brook Ledge Open Welcome, $25,000 SmartPak Grand Prix and then captured first, second and fifth place in the $15,000 KindredBio Open Jumper Prix.

“I’d like to thank Kindred Bio for sponsoring this class,” said Chapot. “It’s great to have them here at HITS and let’s hope we have them around for long time in the future.”

KindredBio is looking forward to 5 more weeks of the HITS on the Hudson Series that will start back up July 20th finishing on September 11th with the Saugerties $1 Million Dollar Grand Prix- FEI CSI-5* the final event in the HITS Triple Crown of Show Jumping.  As a proud platinum sponsor of the HITS Horse Shows Series sponsoring the KindredBio Open Jumper Prix, we congratulate all the horses and riders!

 

About Kindred Biosciences

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.  The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats, and horses.  The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

For more information or to download the corporate presentation, visit www.KindredBio.com. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

 

About HITS, Inc.

HITS, Inc. is a special events management company primarily focused on producing hunter/jumper horse shows. Based in upstate New York in the village of Saugerties, HITS produced its first horse show circuit in Gainesville, Florida in 1982. Since then, HITS has grown into a nationwide company with world-class hunter/jumper circuits in California, Florida, Arizona, New York and Virginia.

HITS produces three of the richest grand prix in the world with the AIG $1 Million Grand Prix in Thermal, California, Great American $1 Million Grand Prix in Ocala, Florida and Saugerties $1 Million Grand Prix FEI CSI-5* in Saugerties, New York – all forming the HITS Triple Crown of Show Jumping. The HITS Championship, held each September at HITS-on-the-Hudson, hosts the HITS $250,000 Junior/Amateur-Owner Jumper Prix, the Stal Hendrix Pre-Green Futurity, and the crown jewels of the hunter discipline: the Diamond Mills $500,000 Hunter Prix Final and the Platinum Performance $250,000 Hunter Prix Final.

For more information and a complete schedule of classes and events, visit www.HitsShows.com. Stay connected with HITS! Join us on Facebook and follow us on Twitter and Instagram. Media should contact the HITS Media Team at 845.246.8833 or e-mail media_info@HitsShows.com.

Kindred Biosciences Announces HITS Sponsorship

San Francisco, CA (May 25, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, is pleased to announce their Platinum Sponsorship of the HITS Horse Show series.  The sponsorship will start this week at the Saugerties, New York facility for the HITS-on-the-Hudson series and will extend through both the HITS Ocala Winter Circuit in Ocala, Florida, and the HITS Desert Circuit in Thermal, California.

Denise Bevers, Co-Founder and Chief Operating Officer, said, “As a company dedicated to developing innovative medications for our horse companions, we are very pleased to be partnering with HITS to sponsor the KindredBio Open Jumper Prix.  With members of the show jumping community on our very own KindredBio team, we look forward to supporting the veterinarians, trainers, and horse owners behind such talented horse and rider athletes.”

“We are honored that KindredBio selected HITS Horse Shows as its first sponsorship in the industry,” said HITS President and CEO Tom Struzzieri. “My team is looking forward to watching this new innovative company grow into something special right before our eyes.”

About Kindred Biosciences

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.  The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats, and horses.  The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

For more information or to download the corporate presentation, visit www.KindredBio.com. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

About HITS, Inc.

HITS, Inc. is a special events management company primarily focused on producing hunter/jumper horse shows. Based in upstate New York in the village of Saugerties, HITS produced its first horse show circuit in Gainesville, Florida in 1982. Since then, HITS has grown into a nationwide company with world-class hunter/jumper circuits in California, Florida, Arizona, New York and Virginia.

HITS produces three of the richest grand prix in the world with the AIG $1 Million Grand Prix in Thermal, California, Great American $1 Million Grand Prix in Ocala, Florida and Saugerties $1 Million Grand Prix FEI CSI-5* in Saugerties, New York – all forming the HITS Triple Crown of Show Jumping. The HITS Championship, held each September at HITS-on-the-Hudson, hosts the HITS $250,000 Junior/Amateur-Owner Jumper Prix, the Stal Hendrix Pre-Green Futurity, and the crown jewels of the hunter discipline: the Diamond Mills $500,000 Hunter Prix Final and the Platinum Performance $250,000 Hunter Prix Final.

For more information and a complete schedule of classes and events, visit www.HitsShows.com. Stay connected with HITS! Join us on Facebook and follow us on Twitter and Instagram. Media should contact the HITS Media Team at 845.246.8833 or e-mail media_info@HitsShows.com.

Contact

Russell Radefeld
KindredBio
russell.radefeld@kindredbio.com
(650) 701-7904